Related Experiment Video
Updated: Jun 11, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation
G Denas1, G Santostasi2, V Pengo1,3
1Cardiology Clinic, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padua University Hospital, Padua, Italy.
Insights
Direct oral anticoagulants (DOACs) offer improved safety over older drugs for stroke prevention in atrial fibrillation. However, ongoing research is vital to address persistent bleeding risks and optimize therapy in specific patient groups.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Medicine
Background:
- Oral anticoagulants are crucial for stroke risk reduction in atrial fibrillation.
- Direct oral anticoagulants (DOACs) have largely replaced Vitamin K antagonists due to better safety profiles.
- Hemorrhagic complications remain a significant concern despite advancements in anticoagulation therapy.
Purpose of the Study:
- To review current knowledge on the safety profiles of available anticoagulants.
- To highlight persistent safety concerns with DOACs in stroke prevention for atrial fibrillation.
- To emphasize the importance of understanding safety in specific patient subgroups.
Main Methods:
- Comprehensive literature search for data on anticoagulant safety profiles.
- Review of existing studies and clinical data on direct oral anticoagulants and Vitamin K antagonists.
- Analysis of expert opinions regarding current anticoagulation pharmacotherapy.
Main Results:
- DOACs represent a significant advancement but do not eliminate safety concerns.
- Bleeding risk scores should guide shared decision-making and risk factor management, not dictate treatment.
- Further investigation is needed into circulating DOAC levels and anticoagulation in vulnerable populations.
Conclusions:
- Enhanced understanding of anticoagulant safety profiles is essential for improving patient care.
- Personalized approaches to anticoagulation, considering patient subgroups, are crucial.
- Continued research into DOACs and anticoagulation strategies will enhance therapeutic safety.
Introduction:
Oral anticoagulant drugs reduce the risk of stroke associated with atrial fibrillation. Vitamin K antagonists, gold standard therapy for decades, have been deposed by the direct oral anticoagulants that exhibit superior safety profiles. However, hemorrhagic complications remain a major concern to anticoagulation.
Areas Covered:
We searched available data in the literature to review the current knowledge on the safety profiles of available anticoagulants.
Expert Opinion:
Despite a relevant leap forward with the introduction of DOACs, safety concerns persist in some fields of the current pharmacotherapy for stroke prevention in atrial fibrillation. In-depth knowledge of the safety profile of available anticoagulants and dealing with safety issues in patient subgroups is of utmost importance. Bleeding risk scores should not be dichotomously used to decide anticoagulation treatment but rather to promote shared decision, identify and correct modifiable risk factors, and set monitoring frequency. Additional issues that wait to be investigated in order to improve the safety of therapy include circulating levels of direct oral anticoagulants and anticoagulation in patient sub-groups: very elderly, frail, those with advanced kidney or liver disease, and so on. Safety may be improved from the in-depth knowledge of safety concerns and therapeutic options.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins